Teva Seeks to Consolidate Price-Fixing, Opioid Lawsuits
Teva Can Challenge Validity of Orexo Patent (Corrected)
Opioid Use Disorder Market Analysis to 2027 - Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, Omeros
Cancer Pain Diagnostics Market 2022 Structure with Top Industry
Orexo Acquires Exclusive US Rights to Commercialize deprexis - IndiaMedToday
Teva Can Challenge Validity of Orexo Patent (Corrected)
Orexo removes overhang on shares with key court win | Evaluate
Orexo
Orexo enters patent infringement litigation against Actavis
Opioid Use Disorder Market Growth to register a CAGR of 8.7% to reach USD US$ 4,911.8 Million by 2028 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, | Medgadget
Suboxone sales down as opioid addiction drug market intensifies
Teva unloads plant, U.S. OTC line to PL Developments | Fierce Pharma
Orexo soars after winning opioid drug appeal against Teva | Reuters
Orexo launches digital therapies for depression, alcohol misuse early in US | pharmaphorum
Orexo partners with Gaia on digital opioid abuse therapeutic | Pharmaphorum
Fast-dissolving opioid dependence tablet wins EU recommendation - Drug Delivery Business
District Court of Delaware rules that Actavis does not infringes with their Suboxone® and Subutex® generics
In opioid case, NY wants to probe Teva's control of Teva USA
Teva, denying 'any liability,' set aside $646M for opioid settlements. Here's why | Fierce Pharma
Orexo sues Actavis and Teva over narcotic dependency treatment
Swedish Pharmaceutical Company: Orexo soars after winning opioid drug appeal against Teva, Health News, ET HealthWorld
In opioid case, NY wants to probe Teva's control of Teva USA
Teva extends global rebrand with tailored marketing messages for caregivers | Fierce Pharma
